Robert Stone: How City of Hope will go national through acquisition of Cancer Treatment Centers of America

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The acquisition of Cancer Treatment Centers of America will allow City of Hope to build a national network of cancer centers that is fundamentally different from those of other cancer centers.

“This will create a one-of-a-kind national cancer-focused system. I’m not aware of anybody else doing that,” Robert Stone, president and CEO of City of Hope, said to The Cancer Letter. 

The two organizations are very different. City of Hope is an NCI-designated comprehensive cancer center based in Southern California and has founded a subsidiary, AccessHope, to provide remote cancer expertise to employers and their health care affiliates. CTCA has been a for-profit, family-owned business that operates cancer centers in Chicago, Atlanta, and Phoenix. 

After decades of aggressive marketing, CTCA has become one of the most recognized brands in the U.S. For example, in the most recent YouGov America survey of most popular hospitals, CTCA ranked second, below Mayo Clinic and above Johns Hopkins Health. 

“When we did our due diligence, we saw that Cancer Treatment Centers of America is one of the most trusted brands among health care consumers in the country,” Stone said. “How the two names are used and come together going forward is something we haven’t fully decided yet. On Day 1 of the new organization, we will communicate that CTCA is part of City of Hope.”

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Paul Goldberg
Editor & Publisher
Table of Contents


An international phase III clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab. 
Paul Goldberg
Editor & Publisher